Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Ciprofloxacin (Cetraxal®) is recommended as an option for use within NHS Wales for the treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms. |
|||
|
|||
Medicine details |
|||
| Medicine name | ciprofloxacin (Cetraxal®) | ||
| Formulation | 2 mg/ml ear drops | ||
| Reference number | 1343 | ||
| Indication | Treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms |
||
| Company | Aspire Pharma Ltd | ||
| BNF chapter | Ear, nose & oropharynx | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1218 | ||
| NMG meeting date | 16/05/2018 | ||
| AWMSG meeting date | 18/07/2018 | ||
| Date of issue | 23/07/2018 | ||
| Date of last review | December 2021 | ||